Abstract:Hepatic encephalopathy (HE) remains a severe neuropsychiatric complication of liver failure. Neuropathological evaluation of material from patients who died in hepatic coma reveals morphologic changes primarily to astrocytes (cytotoxic edema, Alzheimer Type II astrocytosis) accompanied by discreet neuronal changes. Liver failure results in the accumulation in brain of neurotoxic compounds (ammonia, manganese, proinflammatory cytokines, mercaptans, octanoic acid) that may act synergistically to impair neuropsychiatric function. Ammonia and manganese act synergistically to activate mitochondrial benzodiazepine receptors leading to increased production of neuroactive steroids, many of which (allopregnanolone, THDOC) have potent neuroinhibitory properties resulting from activation of a neuromodulatory site on the GABA-A receptor ("increased GABAergic tone"). New evidence demonstrates that proinflammatory cytokines such as tumor necrosis factor alpha (TNFalpha) and the interleukins (IL-1beta, and IL-6) are produced not only by the liver but also by the brain in liver failure. Ammonia and proinflammatory cytokines generated either by intercurrent infection or from hepatocyte necrosis in liver failure act synergistically to decrease the capacity of astrocytes to remove glutamate from the brain extracellular space leading to the activation of glutamate (NMDA) receptors that in turn results in alterations of cell-cell signalling and hyperexcitability. Therapy for HE continues to rely heavily on strategies aimed at reduction of gut ammonia production, increased ammonia removal and, ultimately, liver transplantation. A more complete understanding of pathophysiologic mechanisms has led to novel potential strategies aimed at decreasing both GABAergic tone, glutamate (NMDA) receptor activation and proinflammatory cytokines. Such strategies hold promise for new therapies for HE in the near future.

The Association between Hepatic Encephalopathy and Diabetic Encephalopathy: The Brain-Liver Axis

Multivariate analysis of hepatic encephalopathy occurrence in patients with liver failure

The Role of Intestinal Bacteria and Gut–Brain Axis in Hepatic Encephalopathy

Navigating the Gut-brain Axis: Insights into the Pathogenesis of Hepatic Encephalopathy

Morphological and Pathological Characteristics of Brain in Diabetic Encephalopathy

Progress in the Pathogenesis of Diabetic Encephalopathy: The Key Role of Neuroinflammation

Advancing the understanding of diabetic encephalopathy through unravelling pathogenesis and exploring future treatment perspectives

Pathophysiology of hepatic encephalopathy: The concept of synergism

Modulation of brain energy metabolism in hepatic encephalopathy: impact of glucose metabolic dysfunction

Electroacupuncture Improves Learning and Memory Deficits in Diabetic Encephalopathy Rats by Regulating the Nrf2/HO-1 Pathway

Hepatic encephalopathy: current challenges and future prospects

Microbiota-gut-liver-brain axis and hepatic encephalopathy

Gut Dysbiosis and Blood-Brain Barrier Alteration in Hepatic Encephalopathy: From Gut to Brain

Autophagy and Diabetic Encephalopathy: Mechanistic Insights and Potential Therapeutic Implications

Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis

The neurogliovascular unit in hepatic encephalopathy

The assessment and management of cirrhotic patients with encephalopathy

Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology

Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis

Advances in the diagnosis and treatment of hepatic encephalopathy

The Role of Vitamin D Deficiency in Hepatic Encephalopathy: A Review of Pathophysiology, Clinical Outcomes, and Therapeutic Potential